Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Leber Congenital Amaurosis Market Covering 2025–2034?
The market size for leber congenital amaurosis has experienced steady growth in recent years. This market is projected to expand from $1.01 billion in 2024 to $1.06 billion in 2025, at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the past can be ascribed to a rise in awareness regarding rare eye disorders, increased government funding, enhanced diagnostic techniques, the expansion of ophthalmic research centers, and patient advocacy initiatives.
The leber congenital amaurosis market is anticipated to show substantial expansion in the upcoming years. Its valuation is projected to reach $1.31 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.5%. This expected growth within the forecast period stems from factors such as increasing investment in gene therapy, the rising occurrence of inherited retinal diseases, regulatory authorizations for new therapies, a growing number of clinical trials, and an increase in healthcare expenditure. Significant trends for the forecast period encompass the introduction of CRISPR-based treatments, strengthened collaboration among biotech enterprises, the evolution of personalized medicine, broader application of teleophthalmology, and advancements in retinal imaging technology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp
What Are The Drivers Pushing New Developments In The Leber Congenital Amaurosis Market?
The rising occurrence of inherited retinal disorders is projected to boost the expansion of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are genetic conditions impacting the retina, which is the light-sensitive tissue located at the eye’s rear, crucial for sight. This rise in inherited retinal diseases can be attributed to enhancements in genetic testing, increased awareness and diagnostic capabilities, and extended life expectancies. Progress in genetic testing technology has simplified the diagnosis of inherited retinal diseases, resulting in the detection of a greater number of instances. Leber congenital amaurosis plays a role in furthering knowledge about inherited retinal diseases by uncovering genetic mutations and mechanisms of the disease, which aids in the development of specific therapies and treatments. As an illustration, in January 2025, data from the UK Parliament’s House of Commons Library, a UK-based government administration, indicated that around 25,000 individuals in the UK suffered from inherited retinal diseases in 2024, representing a 2% annual increment. Consequently, the growing incidence of inherited retinal diseases is a key driver for the leber congenital amaurosis market.
What Are The Leading Segments Analyzed In The Leber Congenital Amaurosis Market?
The leber congenital amaurosismarket covered in this report is segmented –
1) By Treatment Type: Gene Therapy; Pharmaceutical Drugs; Retinal Prosthesis; Assistive Devices; Other Treatments
2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth); Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years); Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
3) By Distribution Channel:; Direct Tender; Retail Sales
4) By End User: Hospitals; Specialized Eye Clinics; Ophthalmology Research Centers; Home Care Settings; Other End Users
Subsegments:
1) By Gene Therapy: RPE65 Gene Replacement Therapy; CRISPR-Based Gene Editing; AAV (Adeno-Associated Virus) Vector Therapy; Emerging Experimental Gene Therapies
2) By Pharmaceutical Drugs: Retinoid-Based Therapies; Neuroprotective Agents; Anti-Inflammatory Drugs; Antioxidant Therapies
3) By Retinal Prosthesis: Implantable Retinal Chips; Artificial Retinal Stimulation Devices; Bionic Eye Technology
4) By Assistive Devices: Low Vision Aids; Screen Readers and Braille Devices; Mobility Aids for Vision Impairment
5) By Other Treatments: Stem Cell Therapy; Optogenetics-Based Treatments; Visual Rehabilitation Programs; Nutritional and Dietary Interventions
What Trends Are Expected To Drive The Leber Congenital Amaurosis Market?
Key companies operating within the leber congenital amaurosis market are prioritizing the development of innovative treatments, including RNA-based solutions, to improve vision restoration and disease management. RNA-based treatments utilize RNA molecules to address diseases by specifically targeting genetic processes, examples of which include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. As an illustration, Laboratoires Théa S.A.S., a pharmaceutical company based in France, launched Sepul Bio in January 2025. This dedicated business unit aims to advance RNA therapies for inherited retinal diseases, specifically focusing on sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is well-positioned to make substantial progress in treating these rare genetic conditions.
Which Major Industry Participants Are Leading The Leber Congenital Amaurosis Market Growth?
Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Leber Congenital Amaurosis Market?
North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Leber Congenital Amaurosis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp
Browse Through More Reports Similar to the Global Leber Congenital Amaurosis Market 2025, By The Business Research Company
Congenital Diaphragmatic Hernia Drugs Global Market Report 2025
Vitreoretinal Surgery Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vitreoretinal-surgery-devices-global-market-report
Retinal Biologics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model